Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases

Benjamin D. Goodman, Edward M. Mannina, Sandra K. Althouse, Mary Maluccio, Higinia R. Cárdenes

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: To evaluate long-term outcome and toxicity of stereotactic body radiation therapy (SBRT) for hepatic oligometastases from solid tumors. Methods and materials: Eligible patients had 1 to 3 liver metastases, maximum sum diameter 6 cm, without extrahepatic progression. We treated 106 lesions in 81 patients; 67% with colorectal primaries. Median dose was 5400 cGy in 3 to 5 fractions. Results: At median follow-up of 33 months (2.5-70 months), overall local control was 94% (95% confidence interval, not estimable); Kaplan-Meier estimated 96% at 1 year and 91% at 2, 3, and 4 years. Partial/complete response was observed in 69% of lesions with less than 3% progressing. Median survival time was 33.6 months (95% confidence interval, 29.1-38.4); Kaplan-Meier survival estimates at 1, 2, 3, and 4 years were 89.9%, 68.6%, 44.0%, and 28.0%, respectively. Grade 3 or greater liver toxicity was 4.9%. Conclusion: SBRT is effective for selected patients with hepatic oligometastases with limited toxicities. A phase 3 trial comparing SBRT with "gold-standard" surgical resection is warranted.

Original languageEnglish (US)
Pages (from-to)86-95
Number of pages10
JournalPractical Radiation Oncology
Volume6
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Radiotherapy
Safety
Liver
Confidence Intervals
Survival
Kaplan-Meier Estimate
Gold
Neoplasm Metastasis
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. / Goodman, Benjamin D.; Mannina, Edward M.; Althouse, Sandra K.; Maluccio, Mary; Cárdenes, Higinia R.

In: Practical Radiation Oncology, Vol. 6, No. 2, 01.03.2016, p. 86-95.

Research output: Contribution to journalArticle

Goodman, Benjamin D. ; Mannina, Edward M. ; Althouse, Sandra K. ; Maluccio, Mary ; Cárdenes, Higinia R. / Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. In: Practical Radiation Oncology. 2016 ; Vol. 6, No. 2. pp. 86-95.
@article{7e36c7f118e043b2b62656c507322527,
title = "Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases",
abstract = "Purpose: To evaluate long-term outcome and toxicity of stereotactic body radiation therapy (SBRT) for hepatic oligometastases from solid tumors. Methods and materials: Eligible patients had 1 to 3 liver metastases, maximum sum diameter 6 cm, without extrahepatic progression. We treated 106 lesions in 81 patients; 67{\%} with colorectal primaries. Median dose was 5400 cGy in 3 to 5 fractions. Results: At median follow-up of 33 months (2.5-70 months), overall local control was 94{\%} (95{\%} confidence interval, not estimable); Kaplan-Meier estimated 96{\%} at 1 year and 91{\%} at 2, 3, and 4 years. Partial/complete response was observed in 69{\%} of lesions with less than 3{\%} progressing. Median survival time was 33.6 months (95{\%} confidence interval, 29.1-38.4); Kaplan-Meier survival estimates at 1, 2, 3, and 4 years were 89.9{\%}, 68.6{\%}, 44.0{\%}, and 28.0{\%}, respectively. Grade 3 or greater liver toxicity was 4.9{\%}. Conclusion: SBRT is effective for selected patients with hepatic oligometastases with limited toxicities. A phase 3 trial comparing SBRT with {"}gold-standard{"} surgical resection is warranted.",
author = "Goodman, {Benjamin D.} and Mannina, {Edward M.} and Althouse, {Sandra K.} and Mary Maluccio and C{\'a}rdenes, {Higinia R.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.prro.2015.10.011",
language = "English (US)",
volume = "6",
pages = "86--95",
journal = "Practical Radiation Oncology",
issn = "1879-8500",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases

AU - Goodman, Benjamin D.

AU - Mannina, Edward M.

AU - Althouse, Sandra K.

AU - Maluccio, Mary

AU - Cárdenes, Higinia R.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose: To evaluate long-term outcome and toxicity of stereotactic body radiation therapy (SBRT) for hepatic oligometastases from solid tumors. Methods and materials: Eligible patients had 1 to 3 liver metastases, maximum sum diameter 6 cm, without extrahepatic progression. We treated 106 lesions in 81 patients; 67% with colorectal primaries. Median dose was 5400 cGy in 3 to 5 fractions. Results: At median follow-up of 33 months (2.5-70 months), overall local control was 94% (95% confidence interval, not estimable); Kaplan-Meier estimated 96% at 1 year and 91% at 2, 3, and 4 years. Partial/complete response was observed in 69% of lesions with less than 3% progressing. Median survival time was 33.6 months (95% confidence interval, 29.1-38.4); Kaplan-Meier survival estimates at 1, 2, 3, and 4 years were 89.9%, 68.6%, 44.0%, and 28.0%, respectively. Grade 3 or greater liver toxicity was 4.9%. Conclusion: SBRT is effective for selected patients with hepatic oligometastases with limited toxicities. A phase 3 trial comparing SBRT with "gold-standard" surgical resection is warranted.

AB - Purpose: To evaluate long-term outcome and toxicity of stereotactic body radiation therapy (SBRT) for hepatic oligometastases from solid tumors. Methods and materials: Eligible patients had 1 to 3 liver metastases, maximum sum diameter 6 cm, without extrahepatic progression. We treated 106 lesions in 81 patients; 67% with colorectal primaries. Median dose was 5400 cGy in 3 to 5 fractions. Results: At median follow-up of 33 months (2.5-70 months), overall local control was 94% (95% confidence interval, not estimable); Kaplan-Meier estimated 96% at 1 year and 91% at 2, 3, and 4 years. Partial/complete response was observed in 69% of lesions with less than 3% progressing. Median survival time was 33.6 months (95% confidence interval, 29.1-38.4); Kaplan-Meier survival estimates at 1, 2, 3, and 4 years were 89.9%, 68.6%, 44.0%, and 28.0%, respectively. Grade 3 or greater liver toxicity was 4.9%. Conclusion: SBRT is effective for selected patients with hepatic oligometastases with limited toxicities. A phase 3 trial comparing SBRT with "gold-standard" surgical resection is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84959147800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959147800&partnerID=8YFLogxK

U2 - 10.1016/j.prro.2015.10.011

DO - 10.1016/j.prro.2015.10.011

M3 - Article

VL - 6

SP - 86

EP - 95

JO - Practical Radiation Oncology

JF - Practical Radiation Oncology

SN - 1879-8500

IS - 2

ER -